GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D&D Pharmatech Inc (XKRX:347850) » Definitions » Net Issuance of Debt

D&D Pharmatech (XKRX:347850) Net Issuance of Debt : ₩0 Mil (TTM As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is D&D Pharmatech Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. D&D Pharmatech's net issuance of debt for the three months ended in Sep. 2024 was ₩0 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Sep. 2024 was ₩0 Mil.

D&D Pharmatech Net Issuance of Debt Historical Data

The historical data trend for D&D Pharmatech's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

D&D Pharmatech Net Issuance of Debt Chart

D&D Pharmatech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Issuance of Debt
Get a 7-Day Free Trial - 662.14 6,328.55 3,216.96 1,000.00

D&D Pharmatech Quarterly Data
Dec22 Jun23 Sep23 Dec23 Jun24 Sep24
Net Issuance of Debt Get a 7-Day Free Trial - - - - -

D&D Pharmatech Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

D&D Pharmatech Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of D&D Pharmatech's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

D&D Pharmatech Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D&D Pharmatech Inc (XKRX:347850) » Definitions » Net Issuance of Debt
Comparable Companies
XKRX:053030 XKRX:048410 XKRX:005250 XKRX:005690 XKRX:085660 XKRX:358570 XKRX:372320 XKRX:228760 XKRX:389650 XKRX:226950 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
4th floor, 24, Pangyo-ro 255beon-gil, Bundang-gu, Gyeonggi-do, Sampyeong-dong, I&C Building, Seongnam-si, KOR
Website
http://www.ddpharmatech.com
D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.

D&D Pharmatech Headlines

No Headlines